SCHEMBL21058377

SCHEMBL21058377

CCCC(=O)N[C@H]1C(O)O[C@H](COC(=O)OC(C)C)[C@@H](O)[C@@H]1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PYGB P11216 1/20 0.40
▸ MAPK1 P28482 2/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ TLR4 O00206 2/20 0.36
▸ AMDHD2 Q9Y303 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ LMNA P02545 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ HK1 P19367 3/20 0.33
▸ HK2 P52789 3/20 0.33
▸ PRKD3 O94806 1/20 0.31
▸ PRKCG P05129 1/20 0.31
▸ PRKCB P05771 1/20 0.31
▸ PRKCA P17252 1/20 0.31
▸ PRKCH P24723 1/20 0.31
▸ PRKCI P41743 1/20 0.31
▸ PRKCE Q02156 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21137918 0.88 PYGB (0.41) PYGBMAPK1L3MBTL1TLR4AMDHD2
Hydrochloric Acid SCHEMBL31353002 0.84 PYGB (0.41) PYGBMAPK1L3MBTL1TLR4AMDHD2
SCHEMBL21138301 0.84 NT5E (0.40) PYGBMAPK1TLR4AMDHD2ALDH1A1
SCHEMBL21138039 0.84 PYGB (0.45) PYGBMAPK1L3MBTL1TLR4AMDHD2
SCHEMBL21137953 0.84 PYGB (0.45) PYGBMAPK1L3MBTL1TLR4AMDHD2
SCHEMBL21137988 0.82 PYGB (0.40) PYGBMAPK1L3MBTL1TLR4AMDHD2
SCHEMBL21138114 0.82 PYGB (0.40) PYGBMAPK1L3MBTL1TLR4AMDHD2
SCHEMBL21137980 0.82 PYGB (0.40) PYGBMAPK1L3MBTL1TLR4AMDHD2
SCHEMBL28855878 0.82 PYGB (0.40) PYGBMAPK1L3MBTL1TLR4AMDHD2
Hydrochloric Acid SCHEMBL21058387 0.81 PYGB (0.39) PYGBMAPK1L3MBTL1TLR4AMDHD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353870-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2025-11-20 — — US disclosed
US-12312378-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2025-05-27 — — US disclosed
US-20240051982-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2024-02-15 — — US disclosed
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-08-08 — — US disclosed
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-08-08 — — US disclosed
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-08-08 — — US disclosed
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-07-20 — — US disclosed
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-07-20 — — US disclosed
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-02-28 — — US disclosed
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-02-28 — — US disclosed
CN-115594724-A Glucosamine derivatives for preventing or treating joint diseases 润佳(苏州)医药科技有限公司(CN) 2023-01-13 — — CN disclosed
CN-111971290-B Glucosamine derivatives for preventing or treating joint diseases 润佳(苏州)医药科技有限公司 2022-10-14 — — CN disclosed
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2021-03-18 — — US disclosed
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2021-03-18 — — US disclosed
CN-111971290-A Glucosamine derivatives for preventing or treating joint diseases 润佳(苏州)医药科技有限公司 2020-11-20 — — CN disclosed
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) 2019-06-20 — — US disclosed
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) 2019-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353870-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA PYGB 601/4885MAPK1 846/4885L3MBTL1 4558/4885
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS OGT, UGGT1, GLA PYGB 760/4885MAPK1 887/4885L3MBTL1 3561/4885
US-20240051982-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS OGT, UGGT1, FUT6 PYGB 802/4885MAPK1 599/4885L3MBTL1 4691/4885
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders OGT, UGGT1, GLA PYGB 760/4885MAPK1 887/4885L3MBTL1 3561/4885
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA PYGB 601/4885MAPK1 846/4885L3MBTL1 4558/4885
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA PYGB 601/4885MAPK1 846/4885L3MBTL1 4558/4885
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof OGT, UGGT1, GLA PYGB 601/4885MAPK1 846/4885L3MBTL1 4558/4885
US-12312378-B2 Glucosamine derivatives for the prevention or treatment of joint disorders OGT, UGGT1, FUT6 PYGB 802/4885MAPK1 599/4885L3MBTL1 4691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback